Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
Latest in Cardiology from ACC.org
- Discontinuation of Anticoagulation Following Catheter Ablation of AF: Updates With OCEAN TrialCurrent guidelines for management of atrial fibrillation (AF) recommend continuation of oral anticoagulation (OAC) following successful catheter ablation of AF for patients deemed at elevated thromboembolic risk.
- Novel Sarcopenic Obesity Index Predicts CV RiskA novel sarcopenic obesity index served as a clinically meaningful predictor of cardiovascular risk and lent further insight into accompanying genetics and possible therapeutic targets, according to research published July 1 in JACC.
- Poll Results: Brainstorm: Restarting Anticoagulation After Brain BleedThis poll included a clinical vignette of an 80-year-old man with atrial fibrillation (AF), high thromboembolic risk, and multiple cardiovascular (CV) comorbidities who presented 2 months after a spontaneous lobar intracerebral hemorrhage while receiving reduced-dose apixaban...
- Eagle’s Eye View: Clopidogrel vs. Aspirin Following PCIIn this week’s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM).
- Guest Editorial | Turning Prevention Into Practice: ACC's Coordinated ApproachThe ACC's work in cardiovascular disease (CVD) prevention is entering an important new phase – one that reflects both the urgency of the challenge and the opportunity to deliver lasting impact.